Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JTBC00201 (nirmatrelvir + ritonavir) in mild to moderate COVID-19
NCT05601167Phase 3Completed
- Sponsor
- Promomed
- Start
- Feb 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of nirmatrelvir + ritonavir in coronavirus disease 2019 (COVID-19), sponsored by Promomed. Started Feb 2021; status: completed.
02
Drugs
nirmatrelvir + ritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05601167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05601167.